Press Releases Latest Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates Press Releases Year None20232022202120202019201820172016201520142013 Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update May 31, 2022 Theratechnologies Announces New Head of Investor Relations May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 41 - 50 of 328
Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Jul 28, 2022 Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Jul 27, 2022 Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Jul 14, 2022 Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
Jul 14, 2022 Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Jul 13, 2022 Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management
Jul 12, 2022 CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies